

JunoCOVID-Dx: At a Glance

-What is it?

A special edition product of Juno Viral Health Diagnostics that fully integrates COVID-19 viral detection and tracing.

-Why JUNO?

JUNO Metabolomics is a scientific company with deep expertise in developing viral disease management technology.

-What makes JunoCOVID-Dx a game-changer?

JunoCOVID-Dx offers faster, deeper, and broader levels of detection to combat viruses with a high mutation rate, such as COVID-19.

-Is the product ready for the market?

The beta product is currently being used for clinical trials, and the company is expanding to build a proper infrastructure to meet market demands.

-Is the product FDA approved?

We expect to get approval within the next 45 to 60 days.

If you have more questions, please contact sales@junometabolomics.com



Executive Summary

JunoCOVID-Dx

A Special Edition of Juno Viral Health Diagnostics

"Uncover Unseen Details to Tackle Global Pandemics"

1. Current Challenges in COVID-19 Testing and Tracing


- Lack of effective diagnostic testing prone to produce "false negatives"
 :Current testing is built upon reference libraries for only known viruses
 :Current test-kits designed to test only one viral strain at a time
 *SARS-CoV-2 has over 200 variations deposited in GenBank since December 2019
- Current testing only provides a yes or no result to identify active virus on symptomatic patients leaving asymptomatic patients undetected
- **No automated data traceability** and no real-time outbreak mapping which is critical to further contain the spread of the virus and build future prediction models.

2. What is JunoCOVID-Dx?

JunoCOVID-Dx is a special edition product of Juno Viral Health Diagnostics that features rapid, reliable multiplexed detection of current and emerging viral strains and the ability to capture potential mutations. JunoCovid-Dx offers a simplified and non-invasive home-based or isolated sample collection kit. The assay is fast, highly accurate, and capable of testing high volumes (i.e. 96 tests in less than 10 minutes).

JunoCOVID-Dx

- tests for multiple (+ mutating) viral strains in a single test
- identifies virus in asymptomatic & presymptomatic patients
- automated data traceability for real-time outbreak mapping



PCR Based Test

- tests for one viral strain in a single test
- "yes" or "no" result identifies virus in symptomatic patients only
- single report; no built-in backend data management



Solution Packaging:



JunoCOVID-Dx Kit Home Saliva sample collection kit



JunoCOVID-Dx

- MS Diagnostics
- Multiple Pathogen
 Detection
- No PCR solvents
- No in-lab sample prep
- Minimal reagent use
- Repurpose collected sample for future studies



Juno Informatics

- Cloud-based
- Interconnected
- Notification on emerging strains
- Al-driven real-time 24/7 Data Analysis
- Integrated with current applications



Juno Viral ID Libraries

- Cloud optimized
- Interconnected
- Pluggable into viral screening platform for instance IDs
- Easy integration with existing applications

3. JunoCOVID-Dx: Key Advantages and Main Differentiators

- First in U.S. miniaturized MS platform; highly mobile
- First in building proprietary protein viral libraries for diagnostics
- No PCR solvent no reliance on reagent supply chain that limits large scale testing
- Based on Nobel prize winning technology & FDA approved methods
- Easy outbreak forecasting multiple viral detection in one sample, vs. single virus detection per sample using PCR method
- Enduring and expandable technology; ready for any outbreak
- Clinically driven technology
- A part of Juno Viral Health Diagnostics, the most advanced diagnostic solution in the market for viral outbreaks.
- * JunoCOVID-Dx is working toward FDA Approval completion in the next 45-60 days.

4. Contact JUNO Metabolomics for more information:

Email: sales@junometabolomics.com

Web: https://www.junometabolomics.com/junocovid19